The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 88, Issue 1, 2013, Pages 127-129

  Bazan, N G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; APP; Ataxin 1; CAG repeats; Docosahexaenoic acid; Huntingtin; Misfolding; Retinal pigment epithelial cell

Indexed keywords

15 LIPOXYGENASE 1; ARACHIDONATE 15 LIPOXYGENASE; ATAXIN 1; DOCOSAHEXAENOIC ACID; NEUROPROTECTIN 1; NEUROPROTECTIVE AGENT; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CAG REPEAT; CELL SURVIVAL; CONCENTRATION (PARAMETERS); DNA REPLICATION; ENZYME ACTIVITY; HUMAN; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN MISFOLDING; PROTEIN SYNTHESIS;

ANIMALS; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; DOCOSAHEXAENOIC ACIDS; HOMEOSTASIS; HUMANS; NEURITIS; NEURODEGENERATIVE DISEASES; NEURONS; PROTEIN UNFOLDING; PROTEOSTASIS DEFICIENCIES; UP-REGULATION;

EID: 84872019879     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.08.008     Document Type: Article

References (26)

1. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 6:1204-1222.
2. Kim D., Tsai L.H. Bridging physiology and pathology in AD. Cell 2009, 6:997-1000.
3. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 3:287-303.
4. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
5. Bazan N.G., Musto A.E., Knott E.J. Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Mol. Neurobiol. 2011, 2:216-222.
6. Kim H.Y., Spector A.A., Xiong Z.M. A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. Prostaglandins Other Lipid Mediat. 2011, 96:114-120.
7. Rapoport S.I., Ramadan E., Basselin M. Docosahexaenoic acid (DHA) incorporation into the brain from plasma, as an in vivo biomarker of brain DHA metabolism and neurotransmission. Prostaglandins Other Lipid Mediat. 2011, 96:109-113.
8. Hashimoto M., Hossain S. Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases: beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer's disease. J. Pharmacol. Sci. 2011, 2:150-162.
9. Calon F. Omega-3 polyunsaturated fatty acid in Alzheimer's disease: key questions and partial answers. Curr. Alzheimer Res. 2011, 5:470-478.
10. Astarita G., Piomelli D. Towards a whole-body systems [multi-organ] lipidomics in Alzheimer's disease. Prostaglandins Leukot. Essent. Fatty Acids 2011, 5:197-203.
11. Simopoulos A.P. Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Mol. Neurobiol. 2011, 2:203-215.
12. Cole G.M., Ma Q.L., Frautschy S.A. Dietary fatty acids and the aging brain. Nutr. Rev. 2010, 68:102-111.
13. Marcheselli V.L., Hong S., Lukiw W.J., et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 2003, 44:43807-43817.
14. Mukherjee P.K., Marcheselli V.L., Serhan C.N., Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 2004, 101:8491-8496.
15. Zhao Y., Calon F., Julien C., Winkler J.W., Petasis N.A., Lukiw W.J., Bazan N.G. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated mechanisms in Alzheimer's disease models. PLoS One 2011, 1:e15816.
16. Calandria J.M., Mukherjee P.K., de Rivero Vaccari J.C., Zhu M., Petasis N.A., Bazan N.G. Ataxin-1 poly(Q)-induced proteotoxic stress and apoptosis are attenuated in neural cells by docosahexaenoic acid-derived neuroprotectin D1. J. Biol. Chem. 2012, 28:23726-23739.
17. Mukherjee P.K., Marcheselli V.L., de Rivero VaccariC J.C., Gordon W.C., Jackson F.E., Bazan N.G. Photoreceptor outer segment phagocytosis attenuates oxidative stress-induced apoptosis with concomitant neuroprotectin D1 synthesis. Proc. Natl. Acad. Sci. USA 2007, 32:13158-13163.
18. Bazan N.G., Molina M.F., Gordon W.C. Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu. Rev. Nutr. 2011, 31:321-351.
19. Zoghbi H.Y., Bear M.F. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 2012, 3:a009886.
20. Zoghbi H.Y., Orr H.T. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type-1. J. Biol. Chem. 2009, 12:7425-7429.
21. Lukiw W.J., Cui J.G., Marcheselli V.L., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 10:2774-2783.
22. Astarita G., Jung K.M., Berchtold N.C., et al. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 2010, 9:e12538.
23. Calandria J.M., Bazan N.G. Neuroprotectin D1 modulates the induction of pro-inflammatory signaling and promotes retinal pigment epithelial cell survival during oxidative stress. Adv. Exp. Med. Biol. 2010, 664:663-670.
24. Antony R., Lukiw W.J., Bazan N.G. Neuroprotectin D1 induces dephosphorylation of Bcl-xl in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival. J. Biol. Chem. 2010, 24:18301-18308.
25. Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
26. Sheets K.G., Zhou Y., Ertel M.K, et al. Neuroprotectin D1 attenuates laser-induced choroidal neovascularization in mouse. Mol. Vis. 2010, 16:320-329.